Abstracts tagged "gout"

Abstract Number: 2242 • 2015 ACR/ARHP Annual Meeting
Compliance with Allopurinol Among Hypertensive Patients with Gout Diagnosis and the Relationship to Onset of End-Stage Renal Disease
Sylvie Perreault¹, Javier Nuevo², Scott Baumgartner³ and Robert Morlock⁴, ¹University of Montreal, Montreal, QC, Canada, ²AstraZeneca, Madrid, Spain, Madrid, Spain, ³Ardea Biosciences, Inc., San Diego, CA, ⁴4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: The risk of end-stage renal disease (ESRD) in both hypertension and gout has been examined in the clinical literature. However, the impact of allopurinol…
Abstract Number: 924 • 2015 ACR/ARHP Annual Meeting
Patient and Provider Factors in Optimal Gout Management
Brian Coburn¹, Kayli Bendlin², Harlan Sayles¹ and Ted R. Mikuls¹, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²Pharmacy Service, Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha, NE
Background/Purpose: Gout is the most common inflammatory arthritis worldwide. Despite its prevalence and the availability of effective therapies, studies have consistently characterized gout quality of…
Abstract Number: 2243 • 2015 ACR/ARHP Annual Meeting
Economic Burden of Controlled Gout, Uncontrolled Gout, and Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey
Robert Morlock¹, Natalia M. Flores², Kathy Annunziata³, Jonathan Chapnick⁴ and Javier Nuevo⁵, ¹4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ²Kantar Health, Foster City, CA, ³Kantar Health, Princeton, NJ, ⁴Kantar Health, Horsham, PA, ⁵AstraZeneca, Madrid, Spain, Madrid, Spain
Background/Purpose: Gout is one of the most common forms of inflammatory arthritis and is caused by chronic high serum uric acid (sUA) levels (ie, hyperuricemia),…
Abstract Number: 1334 • 2015 ACR/ARHP Annual Meeting
Bone Erosion in Gout: Relationship with Tophus Urate and Soft Tissue Volumes. a Conventional and Dual Energy CT Study
Mark Sapsford¹, Gregory Gamble², Opetaia Aati², Julie Knight¹, Anne Horne², Anthony Doyle¹ and Nicola Dalbeth², ¹University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Imaging and pathology studies have established the close relationship between intraosseous tophus and bone erosion in gout. The tophus is an organised structure consisting…
Abstract Number: 2244 • 2015 ACR/ARHP Annual Meeting
Risk of Incident Atrial Fibrillation in Gout
Seoyoung C. Kim¹, Jun Liu² and Daniel H. Solomon³, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Atrial fibrillation (AF) is the most common arrhythmia associated with cardiovascular disease and mortality. There are increasing data supporting the role of inflammation in…
Abstract Number: 1335 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Progressive Radiographic Damage in Gout: A Prospective Observational Study
Alastair Eason¹, Meaghan House², Zoe Vincent¹, Julie Knight¹, Paul Tan¹, Anne Horne², Gregory Gamble², Anthony Doyle¹, William J. Taylor³ and Nicola Dalbeth², ¹University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Department of Medicine, University of Otago Wellington, Wellington, New Zealand
Background/Purpose: Radiographic damage is frequently observed in patients with longstanding gout. Although cross-sectional studies have described factors associated with joint damage in gout, there are…
Abstract Number: 2341 • 2015 ACR/ARHP Annual Meeting
Treatment of Gout with Pharmacological Vs. Non-Pharmacological Complementary Therapy in the U.S.: An Internet Survey
Jasvinder A. Singh¹, Nipam Shah², N. Lawrence Edwards³ and H. Ralph Schumacher Jr.⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University fo Alabama at Birmingham, Birmingham, AL, ³University of Florida, Gainsville, FL, ⁴Medicine, Rheumatology, U Penn & VA Med Ctr, Philadelphia, PA
Background/Purpose: The interplay of use of dietary supplement, diet modification and ULT adherence in gout management is not known. Therefore, we aimed to begin to…
Abstract Number: 102 • 2015 ACR/ARHP Annual Meeting
Xanthine Oxidase Gene Variants and Their Association with Blood Pressure and Incident Hypertension: A Population Based Study
Lieke E.J.M. Scheepers¹, Jan A. Staessen^2,3, Lutgarde Thijs², Erika Salvi⁴, Annelies Boonen⁵ and Ilja C.W. Arts⁶, ¹Department of Internal Medicine, Division of Rheumatology, CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre, Maastricht, Netherlands, ²Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology KU Leuven, Department of Cardiovascular Diseases, University of Leuven, Leuven, Belgium, ³R & D Group VitaK, Maastricht University, Maastricht, Netherlands, ⁴Department of Health Sciences, University of Milan, Milan, Italy, ⁵Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁶Department of Epidemiology, CAPHRI School for Public Health and Primary Care, CARIM School for Cardiovascular Diseases, and MaCSBio Maastricht Centre for Systems Biology, Maastricht University, Maastricht, Netherlands
Background/Purpose: Uric acid (UA) has been associated with blood pressure (BP) and hypertension. During the final stage of purine metabolism, xanthine oxidoreductase (XOR) breaks down…
Abstract Number: 1359 • 2015 ACR/ARHP Annual Meeting
Risk Factors for the Development of Gout in HIV Patients: A Retrospective Study
Bibi Ayesha, Rafeeq Ahmed, Richard Peralta, Syed Bokhari, Anupama Menon, Giovanni Franchin and Sridhar Chilimuri, Medicine, Bronx Lebanon Hospital Center, Bronx, NY
Background/Purpose: The interaction between human immunodeficiency virus (HIV) disease and rheumatic disorders has been described as “an unfortunate experiment of nature” that could provide insights…
Abstract Number: 2342 • 2015 ACR/ARHP Annual Meeting
Uric Acid-Lowering Therapy Management Among Rural Veterans Affairs Primary Care Providers
Michael Darley¹, Grant W. Cannon² and Christopher Jackson³, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: ACR guidelines exist for the management of gout including the use of uric acid-lowering therapy. ACR guidelines recommend routine monitoring of uric acid levels…
Abstract Number: 220 • 2015 ACR/ARHP Annual Meeting
A Genome-Wide Association Study Reveals Association of the Transferrin Receptor Locus with Gout
Tony R. Merriman¹, Murray Cadzow², Callum Tanner², Matthew A. Brown³, Katie Cremin⁴, Matthijs Janssen⁵, Tim Jansen⁶, Leo A. Joosten⁷, Timothy Radstake⁸, Philip L. Riches⁹, Anne-Kathrin Tausche¹⁰, Frederic Lioté¹¹, Alex So^12,13, Andre M. van Rij², Gregory T. Jones¹⁴, Lisa K. Stamp¹⁵, Nicola Dalbeth¹⁶ and Cushla McKinney², ¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³The University of Queensland Diamantina Institute, Brisbane, Australia, ⁴Diamantina Institute, University of Queensland, Brisbane, Australia, ⁵Rheumatology Dept, Ziekenhuis Rijnstate, Arnhem, Netherlands, ⁶P O Box 581, Haarlem, Netherlands, ⁷Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁸Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁹Centre for Genomic and Experimental Medicine, Western General Hospital, Edinburgh, United Kingdom, ¹⁰Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ¹¹Rheumatology Department; Inserm UMR-S606; Paris-Diderot University, hôpital Lariboisiere, Paris, France, ¹²Service De Rhumatologie, CHUV, Lausanne, Switzerland, ¹³Department of Rheumatology, CHUV, Lausanne, Switzerland, ¹⁴Surgery, University of Otago, Dunedin, New Zealand, ¹⁵Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ¹⁶Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Acute gouty arthritis results from an innate immune response to monosodium urate (MSU) crystals deposited in the joints and soft tissues of hyperuricaemic individuals.…
Abstract Number: 2027 • 2015 ACR/ARHP Annual Meeting
Development of a Dual Energy Computed Tomography Scoring System for Measurement of Urate Deposition in Gout
Sara Bayat¹, Opetaia Aati², Juergen Rech¹, Alexander Cavallaro³, Michael Lell³, Elizabeth Araujo⁴, Christina Petsch⁴, Lisa K. Stamp⁵, Georg A. Schett⁶, Bernhard Manger¹ and Nicola Dalbeth², ¹Department of Internal Medicine 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Department of Radiology, University of Erlangen-Nuremberg, Department of Radiology, Erlangen, Germany, ⁴Medical Department 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ⁶University of Erlangen-Nuremberg, Erlangen, Germany
Development of a Dual Energy Computed Tomography Scoring System for Measurement of Urate Deposition in Gout Background/Purpose: Dual energy computed tomography (DECT) can visualize urate…
Abstract Number: 2349 • 2015 ACR/ARHP Annual Meeting
The Efficacy and Tolerability of Febuxostat in Hyperuricemic Patients with Severe Renal Impairment
Ji Seon Oh and Seungwon Choi, Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, South Korea
Background/Purpose: Febuxostat has shown to be effective and safe in the treatment of hyperuricemia in patients with mild-to-moderate renal impairment without dose adjustment. However, there…
Abstract Number: 221 • 2015 ACR/ARHP Annual Meeting
Clinical and Genetic Characteristics of Diuretic-Associated Gout: A Case-Control Study
Sirisha Mitnala¹, Amanda Phipps-Green², Christopher Franklin¹, Anne Horne³, Lisa K. Stamp⁴, Tony R. Merriman⁵ and Nicola Dalbeth^1,3, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Dunedin, New Zealand, ³Department of Medicine, University of Auckland, Auckland, New Zealand, ⁴Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ⁵Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: Hyperuricaemia and secondary gout are well-recognised complications of diuretic use. Variants in ABCG2 and SLC2A9 have been identified as the two major genetic risk…
Abstract Number: 2095 • 2015 ACR/ARHP Annual Meeting
Dietary Patterns (DASH, Prudent, Western Diets) and the Risk of Gout in US Women – the Nurses Health Study
Jeewoong Choi¹, Na Lu², Yuqing Zhang³, Sharan K. Rai⁴, Gary C. Curhan⁵ and Hyon K. Choi², ¹Massachusetts College of Pharmacy and Health Sciences, Boston, MA, ²Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³BUSM, Boston, MA, ⁴Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ⁵Renal Division, Brigham and Women's Hospital, Boston, MA
Background/Purpose: There is a remarkable, rising disease burden of gout and associated cardiovascular-metabolic comorbidities (e.g., hypertension in 74% and obesity in 53% of cases in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].